TABLE A2.
Patient Characteristics According to Inclusion Status
| Characteristic | Included | Not Included |
|---|---|---|
| No. (%) | 5,915 (51.9) | 5,485 (48.1) |
| Age at diagnosis, median (IQR) | 55.3 (47.5-63.5) | 57.8 (48.8-66.6) |
| Age at diagnosis, No. (%) | ||
| <40 | 449 (7.6) | 366 (6.7) |
| 40-49 | 1,502 (25.4) | 1,188 (21.7) |
| 50-59 | 1,827 (30.9) | 1,519 (27.7) |
| 60-69 | 1,642 (27.8) | 1,576 (28.7) |
| ≥70 | 495 (8.4) | 836 (15.2) |
| Menopausal status, No. (%) | ||
| Premenopausal | 2,425 (41.7) | 1,873 (34.7) |
| Postmenopausal | 3,388 (58.3) | 3,528 (65.3) |
| Charlson Comorbidity Index, No. (%) | ||
| 0 | 4,520 (82.8) | 3,734 (77.7) |
| ≥1 | 942 (17.2) | 1,071 (22.3) |
| Breast cancer stage, No. (%) | ||
| I | 2,954 (50.4) | 2,527 (47.0) |
| II | 2,339 (39.9) | 2,340 (43.5) |
| III | 572 (9.8) | 511 (9.5) |
| Histology, No. (%) | ||
| Invasive ca. NST | 4,580 (77.5) | 4,257 (77.9) |
| Invasive lobular ca | 760 (12.9) | 689 (12.6) |
| Mixed NST/lobular | 566 (9.6) | 522 (9.5) |
| Grade, No. (%) | ||
| 1 | 1,048 (17.9) | 946 (17.5) |
| 2 | 3,137 (53.6) | 2,872 (53.1) |
| 3 | 1,671 (28.5) | 1,594 (29.5) |
| IHC-defined subtypes, No. (%) | ||
| Hormone receptor+/HER2+ | 624 (10.6) | 549 (10.1) |
| Hormone receptor–/HER2+ | 228 (3.9) | 209 (3.9) |
| Hormone receptor+/HER2– | 4,493 (76.4) | 4,108 (75.8) |
| Hormone receptor–/HER2– | 533 (9.1) | 555 (10.2) |
| Breast cancer surgery type, No. (%) | ||
| None | 2 (<1) | 19 (0.3) |
| Mastectomy | 1,544 (26.1) | 1,518 (27.9) |
| BCS | 4,362 (73.8) | 3,900 (71.7) |
| Lymph node management, No. (%) | ||
| SNLB only or none | 3,764 (63.6) | 3,372 (62.0) |
| Axillary dissection or other | 2,151 (36.4) | 2,071 (38.0) |
| No. (%) | 5,915 (51.9) | 5,485 (48.1) |
| Radiotherapy, No. (%) | ||
| No | 467 (7.9) | 511 (9.4) |
| Yes | 5,447 (92.1) | 4,909 (90.6) |
| Chemotherapy type, No. (%) | ||
| None | 2,740 (46.3) | 2,594 (47.7) |
| Adjuvant | 2,453 (41.5) | 2,045 (37.6) |
| Neoadjuvant or both | 721 (12.2) | 795 (14.7) |
| Endocrine therapy, No. (%) | ||
| TAM ± OFS | 1,551 (26.2) | 1,263 (23.7) |
| AI ± OFS | 2,566 (43.4) | 2,596 (48.7) |
| AI + TAM ± OFS | 772 (13.1) | 410 (7.7) |
| None or OFS only | 1,023 (17.3) | 1,066 (20.0) |
| Household adjusted income €, median (IQR) | 2,013 (1,375-2,750) | 1,750 (1,237-2,475) |
| Financial difficulties, No. (%) | ||
| High | 708 (12.3) | 802 (18.3) |
| Medium | 1,255 (21.8) | 1,051 (23.9) |
| Low | 3,805 (66.0) | 2,538 (57.8) |
| Income level, No. (%) | ||
| Low (lowest tertile) | 1,562 (29.2) | 1,538 (39.0) |
| Medium | 1,795 (33.5) | 1,305 (33.1) |
| High (highest tertile) | 2,000 (37.3) | 1,099 (27.9) |
| Educational level, No. (%) | ||
| Low | 2,182 (37.5) | 2,126 (47.7) |
| Medium | 2,155 (37.1) | 1,419 (31.8) |
| High | 1,476 (25.4) | 916 (20.5) |
NOTE. Income refers to tertiles of household income per consumption unit. Financial difficulties defined according to how monthly household resources allowed participants to live: high (with difficulty), medium (adequately but on the limit), or low (financially comfortable). Educational level: high (high school and three or more years of higher education), medium (secondary school ± 2 years of professional training), and low (no education or primary education).
Abbreviations: AI, aromatase inhibitor; BCS, breast-conserving surgery; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NST, no special type; OFS, ovarian function suppression; SNLB, sentinel lymph node biopsy; TAM, tamoxifen.